Clinical Trial Update: A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) [Phase 2]

View source ↗

Summary

VALOUR is a Phase 2 long-term safety and efficacy study of Verekitug (UPB-101) in adults with severe asthma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Verekitug (UPB-101)

Snippet

Sponsor: Upstream Bio Inc. | Conditions: Severe Asthma | Phase 2 | Status: ACTIVE_NOT_RECRUITING